{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.36","value":"-1.5"},{"groupId":"OG001","spread":"14.57","value":"-2.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"549"},{"groupId":"OG001","value":"259"}],"units":"Participants"}],"description":"The EuroQoL EQ-5D-5L comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 levels: no problems (1 as numerical score), slight problems (2 as numerical score), moderate problems (3 as numerical score), severe problems (4 as numerical score), and extreme problems (5 as numerical score). The total score ranges from 0 to 100. A decrease in score indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"MEAN","populationDescription":"All randomized participants who received at least 1 dose of study drug and had analyzable data at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 49 Day 1 (Day 337)","title":"Change From Baseline In QoL Total Score As Assessed By The European Quality Of Life 5-Dimension 5-Level Questionnaire (EuroQoL EQ-5D-5L)","type":"SECONDARY","unitOfMeasure":"score on a scale"}